RVL Pharmaceuticals (RVLP) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVLP shares.
View RVLP analyst ratings or view top-rated stocks.

3 analysts have issued 1 year target prices for RVL Pharmaceuticals' stock. Their RVLP share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.83 in the next twelve months. This suggests a possible upside of 225.7% from the stock's current price.
View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts.

RVL Pharmaceuticals' stock was trading at $1.12 at the beginning of 2023. Since then, RVLP shares have decreased by 22.3% and is now trading at $0.87.
View the best growth stocks for 2023 here.

RVL Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 65,700 shares, a decline of 24.7% from the April 30th total of 87,300 shares. Based on an average daily trading volume, of 69,300 shares, the short-interest ratio is presently 0.9 days. Approximately 0.1% of the company's stock are short sold.
View RVL Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RVLP earnings forecast.

RVL Pharmaceuticals plc (NASDAQ:RVLP) announced its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.03. The company had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 111.27% and a negative net margin of 152.21%. During the same period in the previous year, the business earned ($0.26) EPS.

RVL Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVLP."

RVL Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (1.26%), Renaissance Technologies LLC (0.70%), Scoggin Management LP (0.50%), Titleist Asset Management LLC (0.11%), Insight Advisors LLC PA (0.08%) and Dimensional Fund Advisors LP (0.07%).

Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RVLP stock can currently be purchased for approximately $0.87.

RVL Pharmaceuticals (NASDAQ:RVLP) has a market capitalization of $86.43 million and generates $49.72 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

The company employs 156 workers across the globe.

RVL Pharmaceuticals' mailing address is 400 Crossing Blvd, Bridgewater, New Jersey 08807-2863. The official website for the company is www.osmotica.com. The company can be reached via phone at (908) 809-1300 or via email at lwilson@insitecony.com.